ストックスクリーナーアプリを入手
21.12
4.30%
0.87
プレマーケット:
21.96
0.84
+3.98%
前日終値:
$20.25
開ける：
$20.39
24時間の取引高:
720.10K
Relative Volume:
1.96
時価総額：
$640.57M
収益：
$339.92M
当期純損益:
$-12.83M
株価収益率:
-49.17
EPS:
-0.4295
ネットキャッシュフロー:
$4.52M
1週間 パフォーマンス:
+0.52%
1か月 パフォーマンス:
+9.32%
6か月 パフォーマンス:
-46.67%
1年 パフォーマンス:
+11.69%
1日の値動き範囲:
$20.23
$21.15
1週間の範囲:
$19.86
$21.20
52週間の値動き範囲:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
名前
Castle Biosciences Inc
セクター
電話
866-788-9007
住所
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
21.12 | 640.57M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
464.61 | 172.66B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.17 | 125.40B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.09 | 44.34B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
127.06 | 35.89B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.44 | 34.90B | 3.77B | 449.25M | 240.68M | 7.8556 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-04-30 | 開始されました | Lake Street | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | BTIG Research | Buy |
| 2019-08-19 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-19 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Castle Biosciences Inc (CSTL) 最新ニュース
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K - Stock Titan
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Institutional Confidence - TradingKey
Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Castle Biosciences Inc (CSTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences president & CEO Derek J. Maetzold sells $86,193 stock - Investing.com Nigeria
Castle Biosciences (CSTL) CEO Maetzold exercises options, trusts sell 4,172 shares - Stock Titan
CSTL (NASDAQ) Rule 144 notice: director sale notice for 4,152 shares - Stock Titan
Castle Biosciences (CSTL) Surpasses 100,000 TissueCypher Test Or - GuruFocus
Castle Biosciences TissueCypher clinical test orders surpass 100,000 milestone - Traders Union
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - StreetInsider
Castle Biosciences’ Barrett’s esophagus test reaches 100k orders - Investing.com
Technical Reactions to CSTL Trends in Macro Strategies - Stock Traders Daily
Castle Biosciences (CSTL) Slips Slightly as Shares Test Near-Term SupportPrice Action Signals - newsline.com
CSTL Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineGrowth Acceleration Report - newsline.com
How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary - Yahoo Finance
Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth - Investing.com
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised - Investing.com
Castle Biosciences (CSTL) CEO sells shares and exercises options under 10b5-1 plan - Stock Titan
CSTL: Raised 2026 guidance after strong Q1 growth and expanded diagnostic test adoption - TradingView
CSTL: Raised 2026 revenue guidance on strong test growth and innovation in dermatology and GI - TradingView
Trading the Move, Not the Narrative: (CSTL) Edition - Stock Traders Daily
Maetzold-related trusts sell shares (CSTL) in multiple Form 144 trades - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant - Stock Titan
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units - Stock Titan
Director at Castle Biosciences (CSTL) granted 11,766 RSUs - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSU compensation award - Stock Titan
Director at Castle Biosciences (CSTL) receives 11,766 RSU equity award - Stock Titan
Castle Biosciences (NASDAQ: CSTL) grants 11,766 RSUs to director - Stock Titan
Is Castle Biosciences Inc (CSTL) a Bargain After 4.7% Drop? GF V - GuruFocus
Castle Biosciences Shareholders Back Board, Governance and Pay - TipRanks
Castle Biosciences (NASDAQ: CSTL) investors approve directors, pay and KPMG - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Downgraded by Zacks Research to "Hold" - MarketBeat
Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know - MSN
Castle Biosciences (CSTL) director receives 13,667 shares via RSUs - Stock Titan
Director Daniel Bradbury adds 13,667 CSTL shares via RSU exercise, boosts direct and trust holdings - Stock Titan
Castle Biosciences (CSTL) director converts 13,667 RSUs into common shares - Stock Titan
Director at Castle Biosciences (CSTL) settles 13,667 RSUs into common stock - Stock Titan
Director at Castle Biosciences (NASDAQ: CSTL) converts 13,667 RSUs to shares - Stock Titan
Director at Castle Biosciences (CSTL) gains 13,667 shares via RSU exercise - Stock Titan
Castle Biosciences (CSTL) director converts 13,667 RSUs into Common Stock - Stock Titan
Castle Biosciences (CSTL) CCO exercises options to add 11,210 shares - Stock Titan
Castle Biosciences Slides 2.08% as Shares Test Support Near $19.73Exhaustion Gap - The Legal Advocate
Castle Biosciences Inc. (CSTL) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest OptimismCEO Earnings Statement - newsline.com
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets - Yahoo Finance
(CSTL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Castle Biosciences Inc (CSTL) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
1.36%
大文字化:
|
ボリューム (24 時間):